Certain of the statements contained in this news release are forward-looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown. Some examples of known risks are: the results of clinical trials, impact of general economic conditions, general conditions in the biotech industry, changes in the regulatory environment in the jurisdictions in which Haemacure does business, stock market volatility, fluctuations in costs, and changes to the competitive environment due to consolidation or otherwise. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. Haemacure disclaims any intention or obligation to update these statements.
Complete financial statements for the quarter ended April 30, 2009 are available on Haemacure's web site, www.haemacure.com, and have been filed on Sedar.
Financial Highlights (unaudited) Quarters ended April 30, 2009 April 30, 2008 -------------- -------------- Sales $18,765 $28,368 General and administrative expenses $631,681 $1,327,551 Research and development expenses $581,164 $668,452 Total expenses $1,252,377 $2,520,807 Net loss $(1,242,150) $(2,504,982) Loss per share $(0.01)
|SOURCE HAEMACURE CORPORATION|
Copyright©2009 PR Newswire.
All rights reserved